The goal of the Career Development Program is to prepare physicians and scientists for independent careers in translational research in sarcoma. It is our hope that the women and men funded through this process will spend their professional lifetimes conducting translational research specifically in this set of diseases and that they will become leaders in their fields of interest. Memorial Sloan-Kettering Cancer Center (MSKCC) is ideally suited for this task, with substantial physical and faculty resources and more than a century of experience training physicians and scientists of the highest quality. Our institutional environment includes a K12 for translational science training and a K30 for the training of clinical investigators. In the Career Development Program, we plan to enhance the formal training programs that already exist at MSKCC. We will encourage more physicians to focus on translational research in sarcoma and will similarly strive to attract basic scientists to devote postdoctoral fellowship training to this quickly evolving field. We will also provide partial support for two new junior faculty investigators every 2 to 3 years who commit their careers to translational research in sarcoma. In our efforts to recruit these investigators, we will draw upon existing programs at MSKCC that recruit, train, and mentor postgraduate scientists and physician-scientists. We will budget at least $150,000 yearly for this program, including $50,000 from the SPORE award itself and at least $100,000 in funds pledged by MSKCC. To continually educate both trainees and SPORE staff, we will utilize regularly scheduled conferences, data presentations by members of the SPORE research projects and cores, and presentations by invited speakers. The Career Development Program will be directed by a Career Development Committee, chaired by Dr. David Spriggs and Dr. Robert Maki.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140146-04
Application #
8515352
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2013
Total Cost
$43,244
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Bennett, Jennifer A; Braga, Ana C; Pinto, Andre et al. (2018) Uterine PEComas: A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors. Am J Surg Pathol 42:1370-1383
Kao, Yu-Chien; Fletcher, Christopher D M; Alaggio, Rita et al. (2018) Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol 42:28-38
Zhang, Jennifer Q; Zeng, Shan; Vitiello, Gerardo A et al. (2018) Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 6:434-447
Fittall, Matthew W; Mifsud, William; Pillay, Nischalan et al. (2018) Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun 9:2150
Antonescu, Cristina R; Agaram, Narasimhan P; Sung, Yun-Shao et al. (2018) A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions. Am J Surg Pathol 42:553-560
Katabi, Nora; Xu, Bin; Jungbluth, Achim A et al. (2018) PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities. Histopathology 72:285-293
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Dickson, Brendan C; Antonescu, Cristina R; Argyris, Prokopios P et al. (2018) Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. Am J Surg Pathol 42:1297-1305

Showing the most recent 10 out of 169 publications